Investment firms attending the 22nd Anglonordic Lifescience Conference

120 Capital/6 Dimensions Capital, 4BIO Capital, A2E Industries, Aditum, Advent Life Sciences, AION Labs, Albion VC, AJYL, ALSA Ventures, Angel Investor, Angelini Ventures, Apposite Capital, ARCH Venture Partners, ARCHIMED Private Equity, Astellas, Axilium Holding AB, BGF Biovision Ventures, BlackRock (Kreos Capital), BNP Paribas Asset Management, Brandon Capital, British Business Bank, Calculus Capital, Caldwell Capital, Cambridge Enterprise Ventures, Cambridge Technology Capital, Cell and Gene Therapy Catapult (Ventures), Claret Capital Partners, Consensus Business Group, CPI Enterprises, Deepbridge Capital, Epidarex Capital, Evolutia Venture Partners, Flerie Invest AB, Forbion, Foresight Group, Future Planet Capital, GL Capital, Gliding Ant Ventures, Global Brain, Gold Nest Capital, Hermes Partners Intl., HINA Bioventures, H Tree Capital, ICG, Illumina Ventures, IPF Partners, JJDC, Kerna Ventures, Kineo Finance, London and Partners / MedCity, LongRiver Investments, Longwall Venture Partners, M Ventures, Maudsley Enterprise, Mazeation, Meltwind, Mid Atlantic Bio Angels, MSD (MGHIF), Momentum Biotech, New Science Fund, NG Bio, Nodenza Venture Partners, Novateur Ventures, o2h Ventures, Octopus Ventures, OMX Ventures, OrbiMed, OSE, Otsuka Pharmaceutical, Panacea Capital, Panmure Liberum Cambridge Capital, Parkinson's UK Virtual Biotech, Peppermint VenturePartners, Polar Capital, Rosetta Capital, RYSE, SCI Ventures, Seventure, Sofinnova Partners, Sound Bioventures, SPRIM Global Investments, Sunstone Life Science Ventures, Syncona Partners, The Pioneer Group, UKI2S, Vesalius Biocapital, XGEN Venture, Zinc.
(89 correct at 18 April 2026).